Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The medical research company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.02. NeoGenomics 2026 Revenue OutlookManagement now expects 2026 revenue of $802 million to $806 million, above the approximately $800.3 million analyst consensus. Needham Raises NeoGenomics Price TargetAnalysts Set New Price TargetsSeveral equities research analysts have recently weighed in on NEO shares. NeoGenomics Price PerformanceThe company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41.